1. Home
  2. ADIL vs INDP Comparison

ADIL vs INDP Comparison

Compare ADIL & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adial Pharmaceuticals Inc

ADIL

Adial Pharmaceuticals Inc

HOLD

Current Price

$2.71

Market Cap

6.4M

Sector

Health Care

ML Signal

HOLD

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$3.78

Market Cap

5.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADIL
INDP
Founded
2010
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4M
5.2M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
ADIL
INDP
Price
$2.71
$3.78
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$37.50
N/A
AVG Volume (30 Days)
1.2M
2.8M
Earning Date
05-13-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.13
$0.92
52 Week High
$5.17
$13.24

Technical Indicators

Market Signals
Indicator
ADIL
INDP
Relative Strength Index (RSI) 57.22 58.14
Support Level $1.53 $1.86
Resistance Level $3.67 $5.60
Average True Range (ATR) 0.47 1.09
MACD -0.00 0.15
Stochastic Oscillator 16.34 47.35

Price Performance

Historical Comparison
ADIL
INDP

About ADIL Adial Pharmaceuticals Inc

Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Share on Social Networks: